Diagnostics company Guardant Health (NASDAQ: GH) announced better-than-expected revenue in Q1 CY2026, with sales up 48.3% year on year to $301.7 million. The company’s full-year revenue guidance of $1.31 billion at the midpoint came in 3.1% above analysts’ estimates. Its GAAP loss of $0.85 per share was 5.9% below analysts’ consensus estimates.
Is now the time to buy GH? Find out in our full research report (it’s free for active Edge members).
Guardant Health (GH) Q1 CY2026 Highlights:
- Revenue: $301.7 million vs analyst estimates of $278.2 million (48.3% year-on-year growth, 8.4% beat)
- EPS (GAAP): -$0.85 vs analyst expectations of -$0.81 (5.9% miss)
- Adjusted EBITDA: -$58.89 million (-19.5% margin, flat year on year)
- The company lifted its revenue guidance for the full year to $1.31 billion at the midpoint from $1.27 billion, a 3.6% increase
- Operating Margin: -40.2%, up from -54.6% in the same quarter last year
- Market Capitalization: $12.23 billion
StockStory’s Take
Guardant Health delivered a strong start to 2026, outperforming Wall Street’s revenue expectations in Q1 as robust demand across its core oncology, biopharma, and screening segments powered top-line growth. Management attributed performance to accelerating adoption of its Shield colorectal cancer test, broad-based growth in oncology testing volumes, and recent product enhancements. Co-CEO Helmy Eltoukhy highlighted that “our commercial flywheel has achieved a new level of velocity,” pointing to the company surpassing $1 billion in trailing 12-month revenue for the first time.
Looking ahead, Guardant Health’s outlook is driven by continued Shield adoption, new product launches, and strategic expansion in biopharma partnerships. Management emphasized investments in commercial infrastructure and data-driven product innovation, with a particular focus on expanding Shield’s reach and advancing the oncology Smart platform. Chief Financial Officer Mike Bell noted, “We plan to continue reinvesting incremental screening gross profit to support commercial expansion during the year,” as the company targets broader patient populations and pursues regulatory milestones that could further expand reimbursement and clinical utility.
Key Insights from Management’s Remarks
Management cited accelerating Shield test adoption, oncology portfolio breadth, and product innovation as the main factors driving financial results and supporting the updated outlook.
-
Shield test momentum: The Shield colorectal cancer screening test experienced rapid volume growth, with approximately 44,000 tests in Q1 compared to 9,000 a year prior. Management credited this to effective direct-to-consumer marketing, new partnerships such as Quest Diagnostics, and high adherence rates of over 90%. Early results from the Quest collaboration are encouraging, with expanded reach into health systems and physician practices.
-
Oncology test growth: Oncology test volumes rose 47% year-over-year, led by the Guardant360 Liquid biopsy and strong uptake of the Reveal minimal residual disease (MRD) assay. The company’s Smart Apps, powered by the InfinityAI engine, contributed to deeper adoption among oncologists and greater share gains in both therapy selection and monitoring.
-
Reveal MRD adoption: Reveal remained Guardant’s fastest-growing product, with volumes increasing over 100% year-over-year. Expansion into new indications, such as therapy response monitoring, is driving the trajectory. Management pointed to ongoing data submissions to Medicare contractor MolDx for new reimbursement opportunities, especially in breast cancer surveillance and immunotherapy monitoring.
-
Biopharma & Data partnerships: The Biopharma & Data segment saw sustained demand, underpinned by new companion diagnostic (CDx) FDA approvals and expanded partnerships with leading pharmaceutical companies. Notable agreements included collaborations with Merck and Nuvalent, as well as real-world evidence contributions to regulatory submissions in Japan.
-
Cost discipline and margin improvement: Non-GAAP gross margin in screening improved to 56%, reflecting higher Shield average selling prices following Medicare rate increases and lower cost per test due to operational efficiencies. Management reaffirmed its commitment to reinvesting gross profit gains into commercial expansion, particularly for the Shield business.
Drivers of Future Performance
Guardant Health’s guidance is built on Shield’s continued volume gains, new product launches, and increased commercial investment, balanced against reimbursement expansion and operational efficiency.
-
Shield test expansion: Management expects further Shield volume growth, supported by nationwide Quest Diagnostics collaboration, ongoing direct-to-consumer campaigns, and improved integration with electronic medical record (EMR) systems. The company also aims to broaden Shield’s reach to patients under 65 as commercial coverage expands, though this may pressure average selling prices.
-
Oncology product launches: New product introductions—including Reveal Ultra and anticipated FDA approval of Guardant360 Liquid for therapy selection—are projected to drive incremental revenue. The company is also investing in development of additional Smart Apps and submitting new indications for reimbursement, which could enhance both adoption and pricing power.
-
Operational efficiency and cash discipline: Guardant is targeting continued improvements in gross margin and free cash flow burn, with plans to automate Shield laboratory processes in 2027. However, management cautioned that incremental profits will be reinvested to support commercial and sales force expansion, potentially moderating near-term operating leverage.
Catalysts in Upcoming Quarters
Over the next several quarters, the StockStory team will be tracking (1) Shield’s progress in expanding commercial coverage and sustaining high adherence rates, (2) the pace and impact of new product launches and regulatory milestones, particularly in oncology, and (3) the evolution of reimbursement for new indications such as MRD and multi-cancer detection. Execution on commercial investments and laboratory automation will also be important indicators of Guardant’s ability to scale profitably.
Guardant Health currently trades at $92.09, in line with $92.26 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
